COPD Flashcards

1
Q

Definition

A

-A common preventable and treatable disease
-characterized by persistent airflow limitation
-usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases.
-The fourth leading cause of death
-Affects more than 10M persons in the U.S.
-Problem with breathing out
Reduced FEV1/ FVC %

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Caused by:

A

Chronic airflow limitation is caused by;

  • A mixture of small airways disease (obstructive bronchiolitis)
  • Parenchymal destruction (emphysema)
  • Emphysema – Destruction of the gas exchanging surfaces of the lung (alveoli)
  • Chronic bronchitis – the presence of cough and sputum production for at least 3 months in each of two consecutive years.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk factors

A
  • Cigarette smoking - Major risk factor for mortality from chronic bronchitis and emphysema.
  • Cigarette smoking - Major risk factor for mortality from chronic bronchitis and emphysema.
  • General exposure to dust (Coal mining, gold mining, and cotton textile dust) and fumes at work.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Airway changes

A

-“air trapping” ( increased residual volume and increased ratio of residual volume to total lung capacity)
-Progressive hyperinflation causes flat diaphragm
-decreased zone of opposition between the diaphragm and abdominal wall
-muscle fibers of flattened diaphragm are shorter
-Distended thoracic cage
Large airways;
-Goblet cell increase in number and in extent
-Bronchi undergo squamous metaplasia
-Smooth muscle hypertrophy and bronchial hyperactivity
-Neutrophil influx
Small airways:
-Goblet cell metaplasia replacing surfactant – secreting clara cells.
-Infiltrations of mononuclear phagocytes
-Smooth muscle cell hypertrophy
-Luminal narrowing by fibrosis
-Excess mucus, edema, and cellular infiltration
-Reduced surfactant
-Respiratory bronchiolitis with mononuclear inflammatory cells
-Loss of bronchiolar attachment

Major site of increased resistance in most individuals with COPD is in airways < 2mm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Emphysema

A
  • is characterized by destruction of gas- exchanging air spaces,
  • respiratory bronchioles, alveolar ducts, alveoli
  • Wall perforation and obliteration
  • bronchoalveolar lavage fluid of smokers
  • Centriacinar- most frequently associated with cigarette smoking; Enlarged air space, Usually most prominent in the upper lobes and superior segments of lower lobes
  • Panacinar – abnormally large spaces evenly distributed within and across acinar units.Usually observed in patients with α1 AT deficiency. Often predilection for the lower lobes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

History/Signs and Symptoms

A
  • Most common symptoms: cough, sputum production, and exertional dyspnea
  • Associated with acute illness or exacerbation
  • Development of exertional dyspnea is insidious
  • Advanced COPD:- worsening dyspnea on exertion
  • Most advanced:- breathlessness while doing simple activities
  • Early stages: entirely normal physical examination.
  • More severe disease – prolonged expiratory phase and may include expiratory wheezing
  • Hyperinflation – barrel chest and enlarged lung volumes with poor diaphragmatic excursion.
  • Cyanosis in the lips and nail beds
  • Systemic wasting, with significant weight loss, bitemporal wasting, and diffuse loss of subcutaneous adipose tissue.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Lab findings

A
  • Pulmonary function test – airflow obstruction with a reduction in FEV1 and FEV1/FVC
  • Worsening disease severity – lung volumes may increase (TLC, FRC, and RV)
  • Diffusing capacity may be reduced
  • ABG and oximetry may demonstrate resting or exertional hypoxemia.
  • α1-AT deficiency test
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tx

A
Stable phase COPD
-smoking cessation
-O2 therapy in chronically hypoxemic patients
-lung volume reduction surgery
Pharmacotherapy
-Smoking cessation
-Bupropion- originally developed as an antidepressant
-Nicotine replacement therapy available as gum
-Transdermal patch
-Bronchodilators, Anticholinergic, Tiotropium 
ß-agonists-
-salmeterol over ipratropium bromide
-inhaled glucocoricoids-
-oral glucocorticoids
-Theophylline
-Oxygen
  • Pulmonary rehabilitation
  • Lung volume reduction surgery
  • Lung transplantation:

Acute exacerbation

  • Bronchodilators
  • Antibiotics
  • Glucocorticoids
  • Oxygen
  • Mechanical ventilator support
How well did you know this?
1
Not at all
2
3
4
5
Perfectly